Table 2.
Baseline clinical characteristics, in-hospital treatment, and bleeding scores of the study sample.
| Parameters | All patients (n=830) |
Bleeding | P-value | |
|---|---|---|---|---|
| Yes (n=52) | No (n=778) | |||
| Clinical presentation | ||||
| NSTEMI, n (%) | 359 (43,2) | 18 (34.6) | 341 (43,8) | 0.194 |
| STEMI, n (%) | 471 (56.8) | 34 (65.4) | 437 (56,2) | |
| Arterial access site | ||||
| Femoral, n (%) | 707 (85.2) | 49 (94.2) | 658 (84.6) | 0.058 |
| Radial, n (%) | 123 (14.8) | 3 (5.8) | 120 (15.4) | |
| Culprit vessel | ||||
| Left anterior descending, n (%) | 362 (43.6) | 26 (50) | 336 (43.2) | > 0.05 |
| Circumflex artery, n (%) | 182 (21.9) | 15 (28.8) | 167 (21.5) | |
| Right coronary artery, n (%) | 257 (31) | 10 (19.3) | 247 (31.7) | |
| Others, n (%) | 29 (3.5) | 1 (1.9) | 28 (3.6) | |
| Killip class | ||||
| Class 1, n (%) | 598 (72.0) | 11 (21.2) | 587 (75.5) | < 0.001 |
| Class 2, n (%) | 139 (16.7) | 16 (30.8) | 123 (15.8) | |
| Class 3, n (%) | 48 (5.8) | 9 (17.3) | 39 (5.0) | |
| Class 4, n (%) | 45 (5.5) | 16 (30.7) | 29 (3.7) | |
| In-hospital time, days | 3.9±1.8 | 4.9±1.9 | 3.8±1.7 | < 0.001 |
| In-hospital treatment | ||||
| Aspirin, n (%) | 817 (98.4) | 50 (96.2) | 767 (98.6) | 0.171 |
| P2Y12 inhibitors switch, n (%) | 94 (11.3) | 11 (21.2) | 83 (10.7) | 0.021 |
| Anticoagulant switch, n (%) | 67 (8.1) | 10 (19.2) | 57 (7.3) | 0.002 |
| Glycoprotein IIb/IIIa inhibitors, n (%) | 85 (10.3) | 18 (34.6) | 67 (8.6) | < 0.001 |
| Bleeding risk score | ||||
| ATRIA score | 1.5±1.7 | 3.76±2.2 | 1.33±1.6 | < 0.001 |
| CRUSADE score | 26.4±11.1 | 41.9±13.1 | 25.4±10.2 | < 0.001 |
| ACUITY-HORİZONS score | 13.2±6.7 | 23.7±5.2 | 12.5±6.2 | < 0.001 |
ACUITY-HORIZONS=Acute Catheterization and Urgent Intervention Triage StrategY-Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction; ATRIA=Anticoagulation and Risk Factors in Atrial Fibrillation; CRUSADE=The Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; NSTEMI=non-ST-segment elevation myocardial infarction; STEMI=ST-segment elevation myocardial infarction